Literature DB >> 28283327

Pharmacokinetics of Perfluorobutane after Intra-Venous Bolus Injection of Sonazoid in Healthy Chinese Volunteers.

Pengfei Li1, Susan Hoppmann2, Ping Du1, Huiling Li1, Paul M Evans3, Siver A Moestue4, Weiyue Yu1, Fang Dong1, Hongchuan Liu1, Lihong Liu1.   

Abstract

Sonazoid is an ultrasound contrast agent based on microbubbles (MB) containing perfluorobutane (PFB) gas. Sonazoid is approved in Japan, Korea and Norway for contrast-enhanced ultrasonography of focal liver lesions and focal breast lesions (Japan only). The objective of this study was to determine the pharmacokinetics (PKs) and safety of Sonazoid in Chinese healthy volunteers (HVs) and to evaluate the potential for ethnic differences in PKs between Chinese and Caucasian HVs. Sonazoid was administered as an intra-venous bolus injection at the clinical dose of 0.12 μL or 0.60 μL MB/kg body weight to two groups of eight Chinese HVs. Expired air and blood samples were collected and analyzed using a validated gas chromatographic tandem mass spectrometry method, and the main PK parameters were calculated. The highest PFB concentrations in blood were observed shortly after intra-venous administration of Sonazoid, and elimination of PFB was rapid. In the 0.12 μL MB/kg body weight cohort, PFB concentrations above the limit of quantification were observed for only 10 to 15 min post-injection. In the 0.60 μL MB/kg body weight cohort, PFB concentrations above the limit of quantification were observed for 60 min post-injection, and the shape of the elimination curve suggested a biphasic elimination profile. The maximum observed concentration (Cmax) values of PFB in blood were 2.3 ± 1.1 and 19.1 ± 9.2 ng/g for the 0.12 and 0.60 μL MB/kg body weight dose groups (mean ± standard deviation). Area under the curve values were 10.1 ± 2.7 and 90.1 ± 38.3 ng × min/g for the 0.12 and 0.60 μL MB/kg body weight dose groups. Cmax values of PFB in exhaled air were 0.35 ± 0.2 and 2.4 ± 0.7 ng/mL for the 0.12 and 0.60 μL MB/kg body weight dose groups. Assessment of laboratory parameters, vital signs, oxygen saturation and electrocardiograms revealed no changes indicative of a concern. The PK profile and safety data generated in the Chinese HVs were comparable to previous data for Caucasian HVs.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Microbubbles; Microspheres; Perfluorobutane; Pharmacokinetics; Sonazoid; Ultrasound

Mesh:

Substances:

Year:  2017        PMID: 28283327     DOI: 10.1016/j.ultrasmedbio.2017.01.003

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  4 in total

Review 1.  Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression.

Authors:  Ying Zhang; Kazushi Numata; Yuewu Du; Shin Maeda
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

2.  Microbubble Size and Dose Effects on Pharmacokinetics.

Authors:  J Angel Navarro-Becerra; Kang-Ho Song; Payton Martinez; Mark A Borden
Journal:  ACS Biomater Sci Eng       Date:  2022-03-31

Review 3.  Contrast-enhanced ultrasonography in interventional oncology.

Authors:  Sriharsha Gummadi; John R Eisenbrey; Andrej Lyshchik
Journal:  Abdom Radiol (NY)       Date:  2018-11

4.  Comparison of Sonazoid contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid MRI for the histological diagnosis of hepatocellular carcinoma.

Authors:  Feiqian Wang; Kazushi Numata; Masahiro Okada; Makoto Chuma; Hiromi Nihonmatsu; Satoshi Moriya; Akito Nozaki; Katsuaki Ogushi; Wen Luo; Litao Ruan; Masayuki Nakano; Masako Otani; Yoshiaki Inayama; Shin Maeda
Journal:  Quant Imaging Med Surg       Date:  2021-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.